title: Outcomes-Based Pricing as a Tool to Ensure Access to Novel but Expensive Biopharmaceuticals.
authors.affiliation: From Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, and Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California.
authors.forename: Daniel M
authors.initials: DM
authors.lastname: Blumenthal
authors.affiliation: From Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, and Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California.
authors.forename: Dana P
authors.initials: DP
authors.lastname: Goldman
authors.affiliation: From Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, and Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California.
authors.forename: Anupam B
authors.initials: AB
authors.lastname: Jena
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics; D000924:Anticholesteremic Agents / Q000191:economics; D001702:Biopharmaceutics / Q000191:economics*; D016527:Drug Costs; D006801:Humans; D017063:Outcome Assessment, Health Care / Q000191:economics*; D000091362:PCSK9 Inhibitors; D011306:Prescription Fees; D014481:United States; D000071449:Proprotein Convertase 9
chemical_list: D000911:Antibodies, Monoclonal; D000924:Anticholesteremic Agents; D000091362:PCSK9 Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9